Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.47 |
| ▸ | HTR2A | P28223 | 8/20 | 0.47 |
| ▸ | HTR2C | P28335 | 8/20 | 0.47 |
| ▸ | HTR2B | P41595 | 8/20 | 0.47 |
| ▸ | DRD2 | P14416 | 7/20 | 0.47 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.38 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 2/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841582 | 0.91 | SIGMAR1 (0.47) | SMN1; SMN2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL6841148 | 0.83 | SIGMAR1 (0.64) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL18815844 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL27081326 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL6841463 | 0.79 | SIGMAR1 (0.60) | SMN1; SMN2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL6841620 | 0.77 | SIGMAR1 (0.64) | SMN1; SMN2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL6836334 | 0.77 | HTR2A (0.42) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL6841619 | 0.76 | SIGMAR1 (0.69) | SMN1; SMN2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL29966360 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL6840784 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2SIGMAR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235808-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| WO-2000075116-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2000-12-14 | — | — | WO | claimed |
| US-20040266802-A1 | Tricyclic analgesics | CALVET ALAIN (US) | 2004-12-30 | — | — | US | disclosed |
| EP-1235808-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2000075116-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266802-A1 | Tricyclic analgesics | OPRM1, OPRL1, OPRD1 | SMN1; SMN2 1008/4885SIGMAR1 11/4885HTR2A 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.